On October 29, Jim Pomonis, American Preclinical Services, Minneapolis, US, gave a talk on the use of animal models of pain in drug discovery. After his talk, there was a panel discussion featuring:
- Anthony Bannon, AbbVie, North Chicago, US
- Iain Chessell, MedImmune, Cambridge, UK
- Jeffrey Mogil, McGill University, Montreal, Canada
- Nick Andrews, Boston Children’s Hospital, Harvard Medical School, US (moderator)
Due to technical problems, the recording of this webinar is unavailable. We apologize for the inconvenience.
Here is Pomonis' abstract of his talk:
Well-publicized failures in pain clinical trials from NK1 antagonists to FAAH inhibitors have led to intense scrutiny being placed on the predictive validity of animal models for chronic pain. However, their predictability has also been supported through successful trials for ziconitide (Prialt®) and the angiotensin II type 2 receptor antagonist, EMA401. And while trial results for the use of tanezumab across multiple indications look promising, results with TRPV1 antagonists have been generally negative, although modest efficacy has been detected. As such, it seems likely that animal models of pain cannot be written off as “bad,” nor can they be touted as “good.” Rather, they have a certain degree of predictivity that we do not fully understand. To this end, we must continue to refine models and behavioral endpoints that improve the predictive nature of preclinical research. However, as we move through the lengthy and iterative process of determining validity of new approaches, it is important that we understand and recognize how the established models as well as the newer approaches fit in the drug discovery process as it stands today. In this webinar, we will examine how well the traditional and newer pain models and assays fit within the workflows, timelines, decision points, and challenges inherent to the drug discovery process.
“The Use of Animal Models of Pain in Drug Discovery: Considerations and Challenges” is the second in a new series of PRF webinars supported by Genentech and MedImmune, with additional site support from other PRF sponsors. All webinars and other site content on PRF are editorially independent; all editorial decisions are made solely by the PRF editors. See previous PRF webinars here.